Celon Labs is an industry leader in the creation and marketing of specialized products that cater to specialized treatment fields. Celon has been successful in bringing a wide variety of products from the laboratory to the market by utilizing its in-house research and development capabilities, operational flexibility, manufacturing expertise, and regulatory knowledge.
Celon Laboratories Overview
Celon Laboratories is a pharmaceutical company that focuses on developing, manufacturing, and marketing pharmaceutical products for the oncology, anti-infective, and critical care markets. Celon Laboratories is a specialty-focused pharmaceutical company. Tablets, capsules, ampoules, vials, pre-filled syringes, and emulsion injections are among the products that come from their facility. Additionally, the company offers contract research manufacturing services, such as formulation development, lyophilization cycle development, quality control testing, stability studies, and regulatory support services.
Celon Labs reviews: Company Background and History
Celon Labs is a company that specializes in the production, marketing, and distribution of specialty pharmaceutical products. It was established in 2007 by Vimal Kumar Kavuru and Vijay Kumar Vasireddy. The oncology and critical care markets are two of the company’s primary markets. It has 520 employees, and it sells its wares in India as well as in over 45 other countries that are considered emerging markets.
When Celon Laboratories Private Limited first began conducting business in 2007, its primary area of concentration was on oncology. Over time, however, the company shifted its attention to another therapy area, namely critical care. Celon has made its presence felt in India and around the world in a relatively short amount of time by taking a robust, growth-oriented approach.
Celon is a market leader in the development and marketing of specialty products that serve niche therapy areas such as oral and injectable oncology as well as critical care. These products include oncolytics.
Celon’s Research and Development capabilities, operational flexibility, manufacturing and regulatory expertise, and so on, have enabled the company to bring a wide variety of products from the laboratory to the market, frequently as the first company to do so after the loss of exclusivity.
Celon Labs Products and R&D
Celon operates in specialty therapy markets, which are characterized by a high demand for sophisticated manufacturing capabilities. In order to achieve this goal, they’ve armed themselves with the most advanced technology available and the most successful business strategies for the industry. Their strategy places primary emphasis on the consumer who ultimately makes the purchase.
Because of their manufacturing infrastructure, they are able to comply with the regulatory requirements of both India and international organizations.
Their knowledge and experience in cutting-edge technology platforms makes it possible for them to develop potential molecules in-house for use in different areas of therapy.
Celon has expertise in the manufacturing of formulations across a broad spectrum thanks to its established product portfolio in ROW markets such as LATAM, Africa, Southeast Asia, and CIS, among others. Today, they are capable of producing formulations in a variety of forms, including liquid, dry powder, lipid, liposomal, polymer-based microspheres, and lyophilized. In addition, they offer a variety of oral solid dosages, ampoules, and vials in which to store and transport these formulations.
Cancer care
Since 2007, Celon’s specialized oncology offering called Vivilon has assisted a significant number of cancer patients in living longer and more fulfilling lives.
The product basket offered by Vivilon addresses solid tumor, hematology, and supportive care in an effort to bolster the armamentarium of the oncology community and improve the standards of cancer care. Their innovative work in the field of hematology resulted in the creation of India’s first bone marrow transplantation range, which has the potential to fulfill an unfulfilled medical need in the field of BMT therapy.
Through its oncology product portfolio, Celon is committed to bringing hope and a longer life expectancy to the field of cancer care.
Critical Care and Wellness
Since 2009, Revilon, the critical care division of Celon labs, has been rekindling patients’ faith and bringing back their health to an uncountable number of seriously ill people.
Revilon’s product basket features a vital range in each of the therapy areas of cardiovascular care, anesthesia care, and intensive care care, catering to the specific needs of these areas.
Products such as liposomal amphotericin, b injection, and propofol mct/lct have added more value to the company’s ability to fulfill the requirements of its clients.
Revilon’s extensive product portfolio is designed to make it easier for critical care specialists to offer patients who are critically ill hope and wellness while also enhancing their own ability to provide care.
Research and Development
The research and development infrastructure that Celon reviews possesses is among the very best in India, and it serves as the company’s manufacturing facilities’ fulcrum. Celon Laboratories, located in Hyderabad, India, has a dedicated research and development center that adheres to the most stringent cGMP norms. This center is state-of-the-art and covers a total area of 5400 square feet. Celon recruits some of the most talented scientists in the country, and the company’s research activities are carried out across a wide range of scientific disciplines, including Medicinal Chemistry, Analytical Research, Novel Process Research, Novel Drug Delivery Research, and Formulation Research, all of which involve platform technologies.
• Celon is a fully integrated pharmaceutical company that can offer its customers the full range of development and manufacturing services needed to get their products from clinical trials to commercial production.
• The services that are provided can be broken down into three primary categories, which are process development services, manufacturing of bulk product (API), and manufacturing of finished products respectively.
• Celon has experience working with a wide range of products, including cytotoxic active pharmaceutical ingredients (APIs), cytotoxic orals, injections, and liposome-based products.
• Celon Laboratories overview has established its presence in the markets of Southeast Asia and Africa, and it is gradually expanding its presence in the markets of the CIS, Latin America, and Eastern Europe. Celon has been able to build business efficiencies for its partner companies by successfully leveraging its manufacturing competency to enter into product alliances and strategic tie-ups.
• Celon’s product portfolio includes more than one hundred different injectable formulations spanning the fields of oncology, anti-infective medicine, and critical care.
• Celon Laboratories Limited has begun operations in the field of oncology. The division kicked off its operations in India with ten oral cytotoxic products that targeted both solid and hematological cancers.
• The company has a robust pipeline consisting of approximately 50 products that are currently undergoing regulatory clearances and are in various stages of development.
Their research and development team has a wealth of experience in the field of formulation creation. They are able to carry out continuous monitoring and evaluation of the development process because the standard operating procedures that they use have been predefined. Their process development is both innovative and non-infringing, which helps them create formulations of the highest quality that are comparable to those developed by innovators. In addition to this, they place a strong emphasis on not only having the best products but also the best process possible for manufacturing those products, all while adhering to pharmacopeial compliance and regulatory standards.
They are able to bring new products to market because of the capabilities in formulations that they have built up.
The regulatory affairs team at Celon ensures compliance with region-specific regulatory standards and guidelines for approvals in world markets on a regular basis so that the company can fulfill orders from customers in a variety of geographic locations.
Conclusion
Celon Laboratories is a pharmaceutical company that is based in India. It was founded in 2003 and has since grown to become a leading company in the field of pharmaceutical formulation.
The company is a fully integrated pharmaceutical company that is able to provide its customers with a wide range of services. Indeed, even today, the company has a robust pipeline of products that are currently undergoing regulatory clearances and are in various stages of development. Overall, they have a strong presence in the pharmaceutical industry because of the capabilities they have built up.